Mahasongkram, K.; Glab-ampai, K.; Kaewchim, K.; Saenlom, T.; Chulanetra, M.; Sookrung, N.; Nathalang, O.; Chaicumpa, W.
Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer. Vaccines 2023, 11, 1826.
https://doi.org/10.3390/vaccines11121826
AMA Style
Mahasongkram K, Glab-ampai K, Kaewchim K, Saenlom T, Chulanetra M, Sookrung N, Nathalang O, Chaicumpa W.
Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer. Vaccines. 2023; 11(12):1826.
https://doi.org/10.3390/vaccines11121826
Chicago/Turabian Style
Mahasongkram, Kodchakorn, Kantaphon Glab-ampai, Kanasap Kaewchim, Thanatsaran Saenlom, Monrat Chulanetra, Nitat Sookrung, Oytip Nathalang, and Wanpen Chaicumpa.
2023. "Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer" Vaccines 11, no. 12: 1826.
https://doi.org/10.3390/vaccines11121826
APA Style
Mahasongkram, K., Glab-ampai, K., Kaewchim, K., Saenlom, T., Chulanetra, M., Sookrung, N., Nathalang, O., & Chaicumpa, W.
(2023). Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer. Vaccines, 11(12), 1826.
https://doi.org/10.3390/vaccines11121826